Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus

Cancer Treatment Reviews

Volumn 41, Issue 9, 2015, Pages 729-741

  Adam, René ^a   de Gramont, Aimery ^b   Figueras, Joan ^c   Kokudo, Norihiro ^d,m   Kunstlinger, Francis ^a   Loyer, Evelyne ^e   Poston, Graeme ^f   Rougier, Philippe ^g   Rubbia Brandt, Laura ^h   Sobrero, Alberto ⁱ   Teh, Catherine ^j   Tejpar, Sabine ^k   Van Cutsem, Eric ^k   Vauthey, Jean Nicolas ^e   Påhlman, Lars ^l  

^a HÔPITAL PAUL BROUSSE   (France)

^b Franco British Institute   (France)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j National Kidney and Transplant Institute Philippines   (Philippines)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Colorectal cancer; Multidisciplinary team management; Surgery; Synchronous colorectal liver metastases; Systemic therapy

Indexed keywords

BEVACIZUMAB; FOLINIC ACID; OXALIPLATIN;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLON RESECTION; COLORECTAL CANCER; COLORECTAL SURGERY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LAPAROSCOPY; LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PREOPERATIVE PERIOD; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; COLORECTAL NEOPLASMS; CONSENSUS; LIVER NEOPLASMS; META ANALYSIS (TOPIC); PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY;

COLORECTAL NEOPLASMS; CONSENSUS; HUMANS; LIVER NEOPLASMS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84944904298     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.06.006     Document Type: Review

References (112)

1. World Health Organization: International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Accessed 17.11.14]. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
2. Lykoudis P.M., O'Reilly D., Nastos K., Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg 2014, 101:605-612.
3. Nordlinger B., Van Cutsem E., Rougier P., Kohne C.H., Ychou M., Sobrero A., et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007, 43:2037-2045.
4. Nordlinger B., Van Cutsem E., Gruenberger T., Glimelius B., Poston G., Rougier P., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992.
5. Simmonds P.C., Primrose J.N., Colquitt J.L., Garden O.J., Poston G.J., Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006, 94:982-999.
6. Borner M.M. Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer - too good to be true?. Ann Oncol 1999, 10:623-626.
7. Manfredi S., Lepage C., Hatem C., Coatmeur O., Faivre J., Bouvier A.M. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244:254-259.
8. Cummings L.C., Payes J.D., Cooper G.S. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007, 109:718-726.
9. Wang X., Hershman D.L., Abrams J.A., Feingold D., Grann V.R., Jacobson J.S., et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 2007, 97:1606-1612.
10. Conrad C., You N., Vauthey J.N. In patients with colorectal liver metastases, can we still rely on number to define treatment and outcome?. Oncology (Williston Park) 2013, 27. 1078, 1083-4, 1086.
11. Linstone HA, Turoff M. The Delphi method. Techniques and applications. Electronic ed.; 2002. http://is.njit.edu/pubs/delphibook/delphibook.pdf.
12. Ebell M.H., Siwek J., Weiss B.D., Woolf S.H., Susman J., Ewigman B., et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004, 69:548-556.
13. Yin Z., Liu C., Chen Y., Bai Y., Shang C., Yin R., et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): simultaneous or delayed?. Hepatology 2013, 57:2346-2357.
14. Ruers T., Punt C., van Coevorden F., Pierie J.P., Borel-Rinkes I., Ledermann J.A., et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012, 23:2619-2626.
15. LiverMetSurvey. International registry of patients operated for colorectal liver metastasis. [accessed 2311.11]. http://www.livermetsurvey.org.
16. Edge S.B., Compton C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
17. Mekenkamp L.J., Koopman M., Teerenstra S., van Krieken J.H., Mol L., Nagtegaal I.D., et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010, 103:159-164.
18. Siriwardena A.K., Mason J.M., Mullamitha S., Hancock H.C., Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol 2014, 11:446-459.
19. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318.
20. Adam R., Frilling A., Elias D., Laurent C., Ramos E., Capussotti L., et al. Liver resection of colorectal metastases in elderly patients. Br J Surg 2010, 97:366-376.
21. Scharitzer M., Ba-Ssalamah A., Ringl H., Kolblinger C., Grunberger T., Weber M., et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 2013, 23:2187-2196.
22. Rojas Llimpe F.L., Di Fabio F., Ercolani G., Giampalma E., Cappelli A., Serra C., et al. Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. Br J Cancer 2014, 111:667-673.
23. Motosugi U., Ichikawa T., Nakajima H., Sou H., Sano M., Sano K., et al. Imaging of small hepatic metastases of colorectal carcinoma: how to use superparamagnetic iron oxide-enhanced magnetic resonance imaging in the multidetector-row computed tomography age?. J Comput Assist Tomogr 2009, 33:266-272.
24. Soyer P., Poccard M., Boudiaf M., Abitbol M., Hamzi L., Panis Y., et al. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology 2004, 231:413-420.
25. Valls C., Andia E., Sanchez A., Guma A., Figueras J., Torras J., et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 2001, 218:55-60.
26. Kulemann V., Schima W., Tamandl D., Kaczirek K., Gruenberger T., Wrba F., et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?. Eur J Radiol 2011, 79:e1-e6.
27. Moulton C.A., Gu C.S., Law C.H., Tandan V.R., Hart R., Quan D., et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 2014, 311:1863-1869.
28. Sahani D.V., Bajwa M.A., Andrabi Y., Bajpai S., Cusack J.C. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg 2014, 259:861-872.
29. de Geus-Oei L.F., Vriens D., van Laarhoven H.W., van der Graaf W.T., Oyen W.J. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009, 50(Suppl. 1):43S-54S.
30. Ruzzenente A., Conci S., Iacono C., Valdegamberi A., Campagnaro T., Bertuzzo F., et al. Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy. J Gastrointest Surg 2013, 17:281-287.
31. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
32. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
33. Boonsirikamchai P., Asran M.A., Maru D.M., Vauthey J.N., Kaur H., Kopetz S., et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol 2011, 197:W1060-W1066.
34. Shindoh J., Loyer E.M., Kopetz S., Boonsirikamchai P., Maru D.M., Chun Y.S., et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012, 30:4566-4572.
35. Yoshita H., Hosokawa A., Ueda A., Ando T., Kajiura S., Kato H., et al. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. Digestion 2014, 89:43-48.
36. Garcia Vicente A.M., Dominguez Ferreras E., Sanchez Perez V., Poblete Garcia V.M., Villa Guzman J.C., Jimenez Aragon F., et al. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET. Eur J Radiol 2013, 82:e255-e261.
37. Lau L.F., Williams D.S., Lee S.T., Scott A.M., Christophi C., Muralidharan V. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Ann Surg Oncol 2014, 21:2420-2428.
38. Piessevaux H., Buyse M., Schlichting M., Van Cutsem E., Bokemeyer C., Heeger S., et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013, 31:3764-3775.
39. Suzuki C., Blomqvist L., Sundin A., Jacobsson H., Bystrom P., Berglund A., et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2011, 23:948-954.
40. Giessen C., Laubender R.P., Fischer von Weikersthal L., Schalhorn A., Modest D.P., Stintzing S., et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 2013, 104:718-724.
41. Modest D.P., Laubender R.P., Stintzing S., Giessen C., Schulz C., Haas M., et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol 2013, 52:956-962.
42. Karagkounis G., Torbenson M.S., Daniel H.D., Azad N.S., Diaz L.A., Donehower R.C., et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013, 119:4137-4144.
43. Stremitzer S., Stift J., Gruenberger B., Tamandl D., Aschacher T., Wolf B., et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012, 99:1575-1582.
44. Vauthey J.N., Zimmitti G., Kopetz S.E., Shindoh J., Chen S.S., Andreou A., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013, 258:619-626.
45. Rubbia-Brandt L., Audard V., Sartoretti P., Roth A.D., Brezault C., Le Charpentier M., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15:460-466.
46. Vauthey J.N., Pawlik T.M., Ribero D., Wu T.T., Zorzi D., Hoff P.M., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072.
47. Blazer D.G., Kishi Y., Maru D.M., Kopetz S., Chun Y.S., Overman M.J., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344-5351.
48. Ribero D., Wang H., Donadon M., Zorzi D., Thomas M.B., Eng C., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
49. Rubbia-Brandt L., Giostra E., Brezault C., Roth A.D., Andres A., Audard V., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007, 18:299-304.
50. Maru D.M., Kopetz S., Boonsirikamchai P., Agarwal A., Chun Y.S., Wang H., et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010, 34:1287-1294.
51. Sebagh M., Allard M.A., Cunha A.S., Ruiz A., Araujo R., Lemoine A., et al. A proposed new method for assessing the pathological response to chemotherapy in resected colorectal liver metastases. Br J Cancer 2014, 111:470-476.
52. Hamady Z.Z., Lodge J.P., Welsh F.K., Toogood G.J., White A., John T., et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg 2014, 259:543-548.
53. Wakai T., Shirai Y., Sakata J., Kameyama H., Nogami H., Iiai T., et al. Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. Int J Clin Exp Pathol 2012, 5:308-314.
54. Yokoyama N., Shirai Y., Ajioka Y., Nagakura S., Suda T., Hatakeyama K. Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer 2002, 94:1642-1647.
55. Holdhoff M., Schmidt K., Diehl F., Aggrawal N., Angenendt P., Romans K., et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis. Clin Cancer Res 2011, 17:3551-3557.
56. Kokudo N., Miki Y., Sugai S., Yanagisawa A., Kato Y., Sakamoto Y., et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002, 137:833-840.
57. Wakai T., Shirai Y., Sakata J., Valera V.A., Korita P.V., Akazawa K., et al. Appraisal of 1 cm hepatectomy margins for intrahepatic micrometastases in patients with colorectal carcinoma liver metastasis. Ann Surg Oncol 2008, 15:2472-2481.
58. Vigano L., Capussotti L., De Rosa G., De Saussure W.O., Mentha G., Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013, 258:731-740.
59. Andreou A., Kopetz S., Maru D.M., Chen S.S., Zimmitti G., Brouquet A., et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg 2012, 256:642-650.
60. Araujo R., Gonen M., Allen P., Blumgart L., DeMatteo R., Fong Y., et al. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol 2013, 20:4312-4321.
61. Lehmann K., Rickenbacher A., Weber A., Pestalozzi B.C., Clavien P.A. Chemotherapy before liver resection of colorectal metastases: friend or foe?. Ann Surg 2012, 255:237-247.
62. Sorbye H., Mauer M., Gruenberger T., Glimelius B., Poston G.J., Schlag P.M., et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 2012, 255:534-539.
63. Loupakis F., Cremolini C., Masi G., Lonardi S., Zagonel V., Salvatore L., et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014, 371:1609-1618.
64. Heinemann V., von Weikersthal L.F., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S.E., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:1065-1075.
65. Venook A., Niedzwiecki D., Lenz H.-J., Innocenti F., Mahoney M., O'Neil B., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-fu/leucovorin (FOLFIRI) or oxaliplatin/5-fu/leucovorin (mFOLFOX6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014, 32. [Abs LBA3].
66. Garufi C., Torsello A., Tumolo S., Ettorre G.M., Zeuli M., Campanella C., et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010, 103:1542-1547.
67. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
68. Adam R., Aloia T., Levi F., Wicherts D.A., de Haas R.J., Paule B., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25:4593-4602.
69. Brouquet A., Overman M.J., Kopetz S., Maru D.M., Loyer E.M., Andreou A., et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 2011, 117:4484-4492.
70. Chang G.J. Challenge of primary tumor management in patients with stage IV colorectal cancer. J Clin Oncol 2012, 30:3165-3166.
71. McCahill L.E., Yothers G., Sharif S., Petrelli N.J., Lai L.L., Bechar N., et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012, 30:3223-3228.
72. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
73. Poultsides G.A., Servais E.L., Saltz L.B., Patil S., Kemeny N.E., Guillem J.G., et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009, 27:3379-3384.
74. Kohne C.-H., Bokemeyer C., Heeger S., Rougier P., Van Cutsem E. Efficacy of chemotherapy+ cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer: analysis of CRYSTAL and OPUS studies. Ann Oncol 2011, 29. [abstract 3576].
75. Andreou A., Aloia T.A., Brouquet A., Dickson P.V., Zimmitti G., Maru D.M., et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013, 257:1079-1088.
76. de Haas R.J., Wicherts D.A., Flores E., Azoulay D., Castaing D., Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?. Ann Surg 2008, 248:626-637.
77. Van Cutsem E., Cervantes A., Nordlinger B., Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl. 3):iii1-iii9.
78. National Institute for Health and Care Excellence. Colorectal cancer: the diagnosis and management of colorectal cancer. [accessed 17.11.14]. http://www.nice.org.uk/guidance/cg131/chapter/guidance.
79. Adam R., De Gramont A., Figueras J., Guthrie A., Kokudo N., Kunstlinger F., et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012, 17:1225-1239.
80. Feng Q., Wei Y., Zhu D., Ye L., Lin Q., Li W., et al. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable - a meta-analysis. PLoS One 2014, 9:e104348.
81. Slesser A.A., Chand M., Goldin R., Brown G., Tekkis P.P., Mudan S. Outcomes of simultaneous resections for patients with synchronous colorectal liver metastases. Eur J Surg Oncol 2013, 39:1384-1393.
82. Reddy S.K., Pawlik T.M., Zorzi D., Gleisner A.L., Ribero D., Assumpcao L., et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007, 14:3481-3491.
83. Lambert L.A., Colacchio T.A., Barth R.J. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000, 135:473-479.
84. Clancy C., Burke J.P., Barry M., Kalady M.F., Calvin C.J. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol 2014, 21:3900-3908.
85. Arbman G., Pahlman L., Glimelius B. The rise and fall of a longed for clinical trial in patients with generalized colorectal cancer. Acta Oncol 2013, 52:1779-1782.
86. Abraham N.S., Young J.M., Solomon M.J. Meta-analysis of short-term outcomes after laparoscopic resection for colorectal cancer. Br J Surg 2004, 91:1111-1124.
87. Schwenk W., Bohm B., Muller J.M. Postoperative pain and fatigue after laparoscopic or conventional colorectal resections. A prospective randomized trial. Surg Endosc 1998, 12:1131-1136.
88. Ohtani H., Tamamori Y., Arimoto Y., Nishiguchi Y., Maeda K., Hirakawa K. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and open colectomy for colon cancer. J Cancer 2012, 3:49-57.
89. Andersson J., Abis G., Gellerstedt M., Angenete E., Angeras U., Cuesta M.A., et al. Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). Br J Surg 2014, 101:1272-1279.
90. Mentha G., Majno P.E., Andres A., Rubbia-Brandt L., Morel P., Roth A.D. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006, 93:872-878.
91. Nordlinger B., Vauthey J.N., Poston G., Benoist S., Rougier P., Van Cutsem E. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 2010, 9:212-218.
92. Karoui M., Penna C., Amin-Hashem M., Mitry E., Benoist S., Franc B., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006, 243:1-7.
93. Brouquet A., Mortenson M.M., Vauthey J.N., Rodriguez-Bigas M.A., Overman M.J., Chang G.J., et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?. J Am Coll Surg 2010, 210:934-941.
94. Avritscher R., De Baere T., Murthy R., Deschamps F., Madoff D.C. Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes. Semin Intervent Radiol 2008, 25:132-145.
95. Adam R., Laurent A., Azoulay D., Castaing D., Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000, 232:777-785.
96. Brouquet A., Abdalla E.K., Kopetz S., Garrett C.R., Overman M.J., Eng C., et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011, 29:1083-1090.
97. Zhang G.Q., Zhang Z.W., Lau W.Y., Chen X.P. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new strategy to increase resectability in liver surgery. Int J Surg 2014, 12:437-441.
98. Watanabe T., Itabashi M., Shimada Y., Tanaka S., Ito Y., Ajioka Y., et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 2015, 20:207-239.
99. Oxenberg J., Papenfuss W., Esemuede I., Attwood K., Simunovic M., Kuvshinoff B., et al. Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol 2015, 22:1533-1539.
100. Prades J., Remue E., van Hoof E., Borras J.M. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 2015, 119:464-474.
101. Shah S., Arora S., Atkin G., Glynne-Jones R., Mathur P., Darzi A., et al. Decision-making in Colorectal Cancer Tumor Board meetings: results of a prospective observational assessment. Surg Endosc 2014, 28:2783-2788.
102. Vasudevan S.P., Cresswell A.B., Wright J.M., Rees M., Stiff D., Wordley A., et al. Close collaboration between local and specialist multidisciplinary teams allows 'fast-tracking' of patients with colorectal liver metastases. Colorectal Dis 2013, 15:1253-1256.
103. Goyer P., Karoui M., Vigano L., Kluger M., Luciani A., Laurent A., et al. Single-center multidisciplinary management of patients with colorectal cancer and resectable synchronous liver metastases improves outcomes. Clin Res Hepatol Gastroenterol 2013, 37:47-55.
104. Vigano L., Langella S., Ferrero A., Russolillo N., Sperti E., Capussotti L. Colorectal cancer with synchronous resectable liver metastases: monocentric management in a hepatobiliary referral center improves survival outcomes. Ann Surg Oncol 2013, 20:938-945.
105. Lordan J.T., Karanjia N.D., Quiney N., Fawcett W.J., Worthington T.R. A 10-year study of outcome following hepatic resection for colorectal liver metastases - the effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol 2009, 35:302-306.
106. Leo F., Venissac N., Poudenx M., Otto J., Mouroux J. Multidisciplinary management of lung cancer: how to test its efficacy?. J Thorac Oncol 2007, 2:69-72.
107. Blazeby J.M., Wilson L., Metcalfe C., Nicklin J., English R., Donovan J.L. Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 2006, 17:457-460.
108. Ye Y.J., Shen Z.L., Sun X.T., Wang Z.F., Shen D.H., Liu H.J., et al. Impact of multidisciplinary team working on the management of colorectal cancer. Chin Med J (Engl) 2012, 125:172-177.
109. Kopetz S., Chang G.J., Overman M.J., Eng C., Sargent D.J., Larson D.W., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27:3677-3683.
110. Jones R.P., Vauthey J.N., Adam R., Rees M., Berry D., Jackson R., et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 2012, 99:1263-1269.
111. Jones R.P., Hamann S., Malik H.Z., Fenwick S.W., Poston G.J., Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 2014, 50:1590-1601.
112. Endoscopy and Cancer Committee of the French Society of Digestive Endoscopy (SFED), French Federation of Digestive Oncology (FFCD) Place of colorectal stents in therapeutic management of malignant large bowel obstructions. Endoscopy 2014, 46:546-552.